We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
5 Top-Ranked ETF Winners of December With More Room for Gains
Read MoreHide Full Article
Wall Street witnessed an upbeat December due to moderation in inflationary pressures, the likelihood of Fed rate cuts in 2024 and decent corporate earnings. All key U.S. equity gauges – the S&P 500, the Dow Jones, the Nasdaq and the Russell 2000 – gained by 1.8%, 1.6%, 2.2% and 4.20%, respectively in the past one month (as of Dec 27, 2023).
As far as rates are concerned, the benchmark treasury yield started the month at 4.22% and was at 3.79% at the end of Dec 26, 2023. Against this backdrop, below we highlight a few ETFs that have a Zacks Rank #1 (Strong Buy) or Zacks Rank #2 (Buy) and topped the performance list in the past one month. This means that these ETFs have further upside potential even after a stupendous rally in December.
ETFs in Focus
Consumer Discretionary
Invesco S&P SmallCap Consumer Discretionary ETF (PSCD - Free Report) ) – Zacks Rank #2 – Up 18.5% Past Month
The Conference Board stated that its consumer confidence index increased to 110.7 this month from a up from a downwardly revised 101.0 in November. The Present Situation Index—based on consumers' assessment of current business and labor market conditions—rose to 148.5 from 136.5 last month.
The consumer confidence index advanced more than analysts’ expectations of 100.9. Confidence among consumers strengthened as they are now feeling much better about future business scenarios, income and job availability. The hopes for Fed rate cuts in 2024 made the matter even better (read: 5 ETFs to Ride High on Strong Holiday Retail Sales).
Small-Caps
JPMorgan BetaBuilders U.S. Small Cap Equity ETF (BBSC - Free Report) – Zacks Rank #1 – Up 16.9% Past Month
Vanguard S&P Small-Cap 600 Value ETF (VIOV - Free Report) – Zacks Rank #2 – Up 16.2%
Small-cap stocks should rally ahead due to cheaper valuation, cooling inflation data and hopes of Fed rate cuts in 2024. Decent GDP growth momentum. A resilient consumer base also supports the rally in small-cap stocks. Apart from these, other factors are contributing to the rally in small-cap stocks. Per strategists, the valuation gap between large and small-cap companies, as well as private and public markets, suggests that merger and acquisition (M&A) activity may pick up.
Cloud Computing
WisdomTree Cloud Computing ETF (WCLD - Free Report) ) – Zacks Rank #1 – Up 16.5% Past Month
Cloud computing, a sector dominated by Amazon, Microsoft, and Alphabet, remains a promising area. The rise of generative AI is a tailwind for the cloud space. Global Cloud Computing Services market is expected to witness a CAGR of 8.4% during the forecast period 2023-2029, per Market Reports World.
Biotech
Invesco Nasdaq Biotechnology ETF (IBBQ - Free Report) ) – Zacks Rank #2 – Up 16.2% Past Month
The biotech sector has shown signs of recovery, with small caps and biotech stocks beginning to demonstrate strength. This recovery is partly driven by breakthroughs in fields like gene editing and immunotherapy, as well as a favorable industry outlook for 2024.
Innovations and successful drug trials have been key drivers in boosting investor confidence and stock prices in the sector. The sector has been seeing an increase in M&A activity. This is especially likely for biotech companies with pipeline assets in late-stage development, as they are attractive targets for acquisitions.
Semiconductor stocks have surged this year, driven by the AI boom, as these companies provide vital components for AI development. Semiconductor ETFs have also been the best-performing ETFs of the last decade, with chips playing a crucial role in various products, from smartphones to data centers. With AI mania remaining strong, the chip space has every reason to outperform ahead.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
5 Top-Ranked ETF Winners of December With More Room for Gains
Wall Street witnessed an upbeat December due to moderation in inflationary pressures, the likelihood of Fed rate cuts in 2024 and decent corporate earnings. All key U.S. equity gauges – the S&P 500, the Dow Jones, the Nasdaq and the Russell 2000 – gained by 1.8%, 1.6%, 2.2% and 4.20%, respectively in the past one month (as of Dec 27, 2023).
As far as rates are concerned, the benchmark treasury yield started the month at 4.22% and was at 3.79% at the end of Dec 26, 2023. Against this backdrop, below we highlight a few ETFs that have a Zacks Rank #1 (Strong Buy) or Zacks Rank #2 (Buy) and topped the performance list in the past one month. This means that these ETFs have further upside potential even after a stupendous rally in December.
ETFs in Focus
Consumer Discretionary
Invesco S&P SmallCap Consumer Discretionary ETF (PSCD - Free Report) ) – Zacks Rank #2 – Up 18.5% Past Month
SPDR S&P Retail ETF (XRT - Free Report) ) – Zacks Rank #2 – Up 15.6%
The Conference Board stated that its consumer confidence index increased to 110.7 this month from a up from a downwardly revised 101.0 in November. The Present Situation Index—based on consumers' assessment of current business and labor market conditions—rose to 148.5 from 136.5 last month.
The consumer confidence index advanced more than analysts’ expectations of 100.9. Confidence among consumers strengthened as they are now feeling much better about future business scenarios, income and job availability. The hopes for Fed rate cuts in 2024 made the matter even better (read: 5 ETFs to Ride High on Strong Holiday Retail Sales).
Small-Caps
JPMorgan BetaBuilders U.S. Small Cap Equity ETF (BBSC - Free Report) – Zacks Rank #1 – Up 16.9% Past Month
Vanguard S&P Small-Cap 600 Value ETF (VIOV - Free Report) – Zacks Rank #2 – Up 16.2%
Small-cap stocks should rally ahead due to cheaper valuation, cooling inflation data and hopes of Fed rate cuts in 2024. Decent GDP growth momentum. A resilient consumer base also supports the rally in small-cap stocks. Apart from these, other factors are contributing to the rally in small-cap stocks. Per strategists, the valuation gap between large and small-cap companies, as well as private and public markets, suggests that merger and acquisition (M&A) activity may pick up.
Cloud Computing
WisdomTree Cloud Computing ETF (WCLD - Free Report) ) – Zacks Rank #1 – Up 16.5% Past Month
Cloud computing, a sector dominated by Amazon, Microsoft, and Alphabet, remains a promising area. The rise of generative AI is a tailwind for the cloud space. Global Cloud Computing Services market is expected to witness a CAGR of 8.4% during the forecast period 2023-2029, per Market Reports World.
Biotech
Invesco Nasdaq Biotechnology ETF (IBBQ - Free Report) ) – Zacks Rank #2 – Up 16.2% Past Month
iShares Biotechnology ETF (IBB - Free Report) ) – Zacks Rank #2 – Up 15.5%
The biotech sector has shown signs of recovery, with small caps and biotech stocks beginning to demonstrate strength. This recovery is partly driven by breakthroughs in fields like gene editing and immunotherapy, as well as a favorable industry outlook for 2024.
Innovations and successful drug trials have been key drivers in boosting investor confidence and stock prices in the sector. The sector has been seeing an increase in M&A activity. This is especially likely for biotech companies with pipeline assets in late-stage development, as they are attractive targets for acquisitions.
Semiconductor
SPDR S&P Semiconductor ETF (XSD - Free Report) – Zacks Rank #1 – Up 15.4%
Semiconductor stocks have surged this year, driven by the AI boom, as these companies provide vital components for AI development. Semiconductor ETFs have also been the best-performing ETFs of the last decade, with chips playing a crucial role in various products, from smartphones to data centers. With AI mania remaining strong, the chip space has every reason to outperform ahead.